These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1052 related articles for article (PubMed ID: 8722360)

  • 1. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
    Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
    Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.
    de Medeiros CR; Moreira VA; Pasquini R
    Bone Marrow Transplant; 2000 Aug; 26(4):443-4. PubMed ID: 10982292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
    Maltezou H; Whimbey E; Abi-Said D; Przepiorka D; Champlin R; Goodrich J
    Bone Marrow Transplant; 1999 Sep; 24(6):665-9. PubMed ID: 10490734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation.
    Vij R; Khoury H; Brown R; Goodnough LT; Devine SM; Blum W; Adkins D; DiPersio JF
    Bone Marrow Transplant; 2003 Oct; 32(7):703-7. PubMed ID: 13130318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
    Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
    Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
    Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
    Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989.
    Atkinson K; Nivison-Smith I; Dodds A; Concannon A; Milliken S; Downs K
    Bone Marrow Transplant; 1998 Apr; 21(7):691-5. PubMed ID: 9578309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.